COPDi

(redirected from chronic obstructive pulmonary disease)
Also found in: Dictionary, Thesaurus, Medical, Legal, Encyclopedia, Wikipedia.
Related to chronic obstructive pulmonary disease: chronic bronchitis, asthma, COPD, emphysema
AcronymDefinition
COPDiChronic Obstructive Pulmonary Disease
COPDiCommand Officer Professional Development and Improvement (Montgomery County, MD)
References in periodicals archive ?
WASHINGTON -- On behalf of the 24 million Americans living with Chronic Obstructive Pulmonary Disease (COPD), the third leading cause of death in the U.
As time goes on, people with chronic obstructive pulmonary disease may experience breathlessness when walking even a short distance.
Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Chronic Obstructive Pulmonary Disease (COPD) Therapeutics market revenues data from 2005 to 2009, forecast for eight years to 2017.
Understand the key epidemiologic risk factors associated with chronic obstructive pulmonary disease.
Chronic Obstructive Pulmonary Disease (COPD) Therapeutics under Investigation by Universities/Institutes
This is the beginning of a historic new partnership with the COPD Foundation," says Ashley Petrylak, Publisher of COPD: Journal of Chronic Obstructive Pulmonary Disease.
GlobalData estimated the chronic obstructive pulmonary disease (COPD) market to be worth $7.
4 Centers for Disease Control and Prevention, Facts About Chronic Obstructive Pulmonary Disease, August 2003.
Nearly 3/4th of chronic obstructive pulmonary disease patients are from lower socioeconomic group 72% (n: 36) and rest were from middle class 28% (n: 14).
The Japanese Ministry of Health, Labour and Welfare (MHLW) has reportedly approved Relvar Ellipta (fluticasone furoate / vilanterol 100/25 mcg) for the relief of various symptoms with chronic obstructive pulmonary disease (chronic bronchitis, pulmonary emphysema) (in the case where concurrent use of inhaled corticosteroid and long-acting inhaled beta2 agonist is required).
This report provides comprehensive information on the therapeutic development for Chronic Obstructive Pulmonary Disease (COPD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases.
Objective: To compare the change in P-wave amplitude and axis before and after 24 hours of the treatment of chronic obstructive pulmonary disease exacerbation.
Full browser ?